Neurex Corporation

Elan Pharmaceuticals, Inc.

Karen L Valentino

George P Miljanich

Kishor Chandra Gohil

Tejinder Singh

Alan Justice

Stephen S Bowersox

James A Fox

Robert S Bitner

Donald H Yamashiro

Makoto Tsubokawa

A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.

Method for enhancing analgesia

Method of selecting a compound for producing analgesia

Method of treating inflammation

Methods for producing analgesia

Disclosed are novel omega conotoxin peptides effective in producing analgesia.

Omega conopeptide compositions

A method and compositions for reducing neuronal damage related to an ischemic condition in a mammalian subject are described. The method includes administration of a voltage-gated calcium channel-blocking compound to the subject, 4-24 hours after the onset of the ischemic condition. Such a calcium channel blocking compound is effective to block norepinephrine release in mammalian CNS neuronal cells and is characterized by specific, high affinity binding to omega-conotoxin MVIIA binding sites. Also disclosed are novel peptide structures useful in the treatment method of the invention.

Delayed treatment method of reducing ischemia-related neuronal damage

A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.

Screening method for neuroprotective compounds

A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.

Method of producing analgesia

Method of reducing neuronal damage using omega conotoxin peptides

A method of reducing neuronal damage related to an ischemic condition in a human patient, such as stroke-induced damage, by administration of a binding/inhibitory omega-conotoxin peptide.

Growing community of inventors

San Carlos, CA, United States of America

Karen L Valentino